Essential thrombocytosis: Difference between revisions
No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
Line 17: | Line 17: | ||
{{Essential thrombocytosis}} | {{Essential thrombocytosis}} | ||
{{CMG}} | {{CMG}} | ||
{{SK}} Essential thrombocythemia, primary thrombocythemia | |||
==[[Essential thrombocytosis overview|Overview]]== | ==[[Essential thrombocytosis overview|Overview]]== |
Revision as of 20:57, 12 February 2015
For patient information, click here
Template:DiseaseDisorder infobox
Essential thrombocytosis Microchapters |
Differentiating Essential thrombocytosis from other Diseases |
---|
Diagnosis |
Treatment |
Essential thrombocytosis On the Web |
American Roentgen Ray Society Images of Essential thrombocytosis |
Risk calculators and risk factors for Essential thrombocytosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Essential thrombocythemia, primary thrombocythemia
Overview
Classification
Historical Perspective
Pathophysiology
Epidemiology & Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications & Prognosis
Diagnosis
History & Symptoms | Physical Examination | Staging | Lab Tests | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies | Diagnostic criteria
Treatment
Medical Therapy | Special care related to pregnancy | Surgery | Primary Prevention | Secondary Prevention
Resources
- Cancerbackup Essential Thrombocytosis page
- CMPD Education Foundation
- MPD Foundation and Research Alliance - Register for a free newsletter
- Overview of Agrylin, the tradename for anagrelide hydrochloride